LipoCure is developing a number of therapeutics utilizing proprietary liposome-based nano drugs with novel drug-loading capabilities and drug-release mechanisms. LipoCure's proprietary platform implements an approach that allows for remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. This technology is designed to produce an enhanced permeability and retention effect, a significantly improved therapeutic effect, and reduced side effects. It can be used in conjunction with several well-established drugs used for the treatment of rheumatoid arthritis, multiple sclerosis, and cancer. LipoCure's founder is professor Yechezkel Barenholz, the co-developer of Doxil.
Cumulative Funding Raised Over Time ($)
Employees Over Time
LipoCure Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 4, 2018
www.businesswire.com
Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure